Success Metrics

Clinical Success Rate
81.8%

Based on 478 completed trials

Completion Rate
82%(478/584)
Active Trials
168(18%)
Results Posted
58%(276 trials)
Terminated
106(12%)

Phase Distribution

Ph not_applicable
30
3%
Ph phase_3
163
18%
Ph early_phase_1
4
0%
Ph phase_1
295
32%
Ph phase_4
21
2%
Ph phase_2
396
43%

Phase Distribution

299

Early Stage

396

Mid Stage

184

Late Stage

Phase Distribution909 total trials
Early Phase 1First-in-human
4(0.4%)
Phase 1Safety & dosage
295(32.5%)
Phase 2Efficacy & side effects
396(43.6%)
Phase 3Large-scale testing
163(17.9%)
Phase 4Post-market surveillance
21(2.3%)
N/ANon-phased studies
30(3.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.2%

478 of 627 finished

Non-Completion Rate

23.8%

149 ended early

Currently Active

168

trials recruiting

Total Trials

914

all time

Status Distribution
Active(189)
Completed(478)
Terminated(149)
Other(98)

Detailed Status

Completed478
Terminated106
Recruiting99
unknown97
Active, not recruiting69
Withdrawn43

Development Timeline

Analytics

Development Status

Total Trials
914
Active
168
Success Rate
81.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (0.4%)
Phase 1295 (32.5%)
Phase 2396 (43.6%)
Phase 3163 (17.9%)
Phase 421 (2.3%)
N/A30 (3.3%)

Trials by Status

suspended10%
unknown9711%
enrolling_by_invitation30%
not_yet_recruiting182%
terminated10612%
completed47852%
active_not_recruiting698%
withdrawn435%
recruiting9911%

Recent Activity

Clinical Trials (914)

Showing 20 of 914 trialsScroll for more
NCT00400946Phase 3

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

Completed
NCT05645718Phase 2

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Recruiting
NCT03488225Phase 2

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

Terminated
NCT07072585Phase 2

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Not Yet Recruiting
NCT02981628Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT05564390Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Recruiting
NCT03914625Phase 3

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Active Not Recruiting
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT06034470Phase 1

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Active Not Recruiting
NCT00792948Phase 2

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT02003222Phase 3

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT07735117Phase 3

Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML

Not Yet Recruiting
NCT04293562Phase 3

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Recruiting
NCT07507760Phase 2

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

Recruiting
NCT02112916Phase 3

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Active Not Recruiting
NCT02443077Phase 3

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Active Not Recruiting
NCT02101853Phase 3

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT05955261Phase 2

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Suspended
NCT06124157Phase 2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT07724457Phase 2

Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
914